IDE-397 is under clinical development by Ideaya Biosciences and currently in Phase II for Bladder Cancer. According to GlobalData, Phase II drugs for Bladder Cancer have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how IDE-397’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IDE397 is under development for the treatment of solid tumor, non-small cell lung cancer, pancreatic cancer, adenoid cystic carcinoma (ACC), thymic cancer, colorectal cancer, esophageal, gastric, bladder, head and neck cancer. They act by targeting MAT2A (methionine adenosyltransferase 2A) in tumor cells having MTAP gene deletion. The drug candidates are developed based on synthetic lethality drug discovery platform. It is administered through oral route.
Ideaya Biosciences overview
Ideaya Biosciences (Ideaya) is a precision medicine company which develops oncology therapeutics. The company’s lead product candidate IDE196, a protein kinase C (PKC) inhibitor, targets cancers with GNAQ and GNA11 mutations. It develops small molecule inhibitors based on synthetic lethality against known and novel targets. Ideaya also provides solutions for treating tumors with genetic mutations in homologous recombination deficiency(HRD) and high microsatellite instability (MSI). The company collaborates with Novartis Institute for Biomedical Research, Pfizer Inc, Boston Children’s Hospital, Cancer Research UK and, other academic and research institutes for cancer biology, immunology, and small molecule drug discovery. Ideaya is headquartered in South San Francisco, California, the US.
For a complete picture of IDE-397’s drug-specific PTSR and LoA scores, buy the report here.